<p>在 Google 搜索和 AI 回答中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开 Google</p>
<p>在 Google 上添加</p>
<p>马萨诸塞州剑桥，2026 年 6 月 19 日（全球新闻稿）——CAMP4 Therapeutics Corporation（“CAMP4” 或 “公司”）（纳斯达克：CAMP）是一家临床阶段的生物制药公司，正在开发一系列针对 RNA 的治疗药物，旨在上调基因表达，以恢复健康的蛋白质水平，治疗广泛的遗传疾病。公司今天宣布，在 2026 年 6 月 15 日（“授予日期”），公司董事会的薪酬委员会向三名新聘员工授予了购买公司普通股总计 39,000 股的非合格股票期权，作为该员工入职公司的重要诱因，符合纳斯达克上市规则 5635(c)(4)（“诱因授予”）。</p>
<p>每项诱因授予的期限为十年，行使价格为每股 3.96 美元，等于授予日期时 CAMP4 普通股的收盘价。诱因授予将在四年内逐步归属，其中 25% 的股份将在员工入职公司一周年时归属，随后其余的期权将在 36 个月内按月均等归属，前提是员工在适用的归属日期继续为 CAMP4 服务。每项诱因授予均根据公司的 2026 年诱因计划及适用的非合格股票期权协议授予，并受其条款和条件的约束。</p>
<p><strong>关于 CAMP4 Therapeutics</strong></p>
<p>CAMP4 正在开发针对广泛遗传疾病的疾病修饰治疗，这些疾病通过增强健康蛋白质可能提供治疗益处。我们的方法通过利用基因控制的基本机制来增强 mRNA。为了增强 mRNA，我们的治疗性 ASO 药物候选物针对调控 RNA（regRNAs），这些 RNA 在转录因子上局部作用，是基因表达的主要调控因子。CAMP4 的专有 RAP 平台®能够绘制 regRNAs 并生成旨在针对与基因相关的 regRNAs 的治疗候选物，这些基因与超过 1,200 种单倍体不足和隐性部分功能丧失疾病相关，其中适度增加蛋白质表达可能具有临床意义。有关更多信息，请访问 camp4tx.com。</p>
<p><strong>联系方式</strong></p>
<p><strong>投资者关系：</strong></p>
<p>Sara Michelmore</p>
<p>Milestone Advisors</p>
<p>sara@milestone-advisorsllc.com</p>
<p><strong>媒体：</strong></p>
<p>Sofia Bermudez</p>
<p>LifeSci Communications</p>
<p>sbermudez@lifescicomms.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjME9EQTFOaU0zTmpZME9URTJJekl5TmpFM01UUT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjME9EQTFOaU0zTmpZME9URTJJekl5TmpFM01UUT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGYzOWFjYmYtMDg3Yi00YjM0LWE0OTctOWZiM2E4MjI4MDE5LTEyNzMyNjQtMjAyNi0wNi0xOS1lbg==/tiny/CAMP4-Therapeutics.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGYzOWFjYmYtMDg3Yi00YjM0LWE0OTctOWZiM2E4MjI4MDE5LTEyNzMyNjQtMjAyNi0wNi0xOS1lbg==/tiny/CAMP4-Therapeutics.png"/></p>

CAMP

<p>CAMP4 Therapeutics 宣布根据纳斯达克上市规则 5635(c)(4) 进行激励授予。2026 年 6 月 15 日，公司向三名新聘员工授予了 39,000 股非合格股票期权。每个期权的有效期为十年，行使价格为每股 3.96 美元，并在四年内逐步归属</p>

<p>See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google</p>
<div class="lb-trans"><p>在 Google 搜索和 AI 回答中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开 Google</p>
</div><p>Add on Google</p>
<div class="lb-trans"><p>在 Google 上添加</p>
</div><p>CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 39,000 shares of the Company’s common stock to three newly hired employees of the Company, each as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).</p>
<div class="lb-trans"><p>马萨诸塞州剑桥，2026 年 6 月 19 日（全球新闻稿）——CAMP4 Therapeutics Corporation（“CAMP4” 或 “公司”）（纳斯达克：CAMP）是一家临床阶段的生物制药公司，正在开发一系列针对 RNA 的治疗药物，旨在上调基因表达，以恢复健康的蛋白质水平，治疗广泛的遗传疾病。公司今天宣布，在 2026 年 6 月 15 日（“授予日期”），公司董事会的薪酬委员会向三名新聘员工授予了购买公司普通股总计 39,000 股的非合格股票期权，作为该员工入职公司的重要诱因，符合纳斯达克上市规则 5635(c)(4)（“诱因授予”）。</p>
</div><p>The Inducement Grants each have a ten-year term and an exercise price per share of $3.96, which is equal to the closing price of CAMP4’s common stock as of the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service with CAMP4 through the applicable vesting dates. Each Inducement Grant was granted pursuant to, and is subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable non-qualified stock option agreement.</p>
<div class="lb-trans"><p>每项诱因授予的期限为十年，行使价格为每股 3.96 美元，等于授予日期时 CAMP4 普通股的收盘价。诱因授予将在四年内逐步归属，其中 25% 的股份将在员工入职公司一周年时归属，随后其余的期权将在 36 个月内按月均等归属，前提是员工在适用的归属日期继续为 CAMP4 服务。每项诱因授予均根据公司的 2026 年诱因计划及适用的非合格股票期权协议授予，并受其条款和条件的约束。</p>
</div><p><strong>About CAMP4 Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 CAMP4 Therapeutics</strong></p>
</div><p>CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.</p>
<div class="lb-trans"><p>CAMP4 正在开发针对广泛遗传疾病的疾病修饰治疗，这些疾病通过增强健康蛋白质可能提供治疗益处。我们的方法通过利用基因控制的基本机制来增强 mRNA。为了增强 mRNA，我们的治疗性 ASO 药物候选物针对调控 RNA（regRNAs），这些 RNA 在转录因子上局部作用，是基因表达的主要调控因子。CAMP4 的专有 RAP 平台®能够绘制 regRNAs 并生成旨在针对与基因相关的 regRNAs 的治疗候选物，这些基因与超过 1,200 种单倍体不足和隐性部分功能丧失疾病相关，其中适度增加蛋白质表达可能具有临床意义。有关更多信息，请访问 camp4tx.com。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><p><strong>Investor Relations:</strong></p>
<div class="lb-trans"><p><strong>投资者关系：</strong></p>
</div><p>Sara Michelmore</p>
<div class="lb-trans"><p>Sara Michelmore</p>
</div><p>Milestone Advisors</p>
<div class="lb-trans"><p>Milestone Advisors</p>
</div><p>sara@milestone-advisorsllc.com</p>
<div class="lb-trans"><p>sara@milestone-advisorsllc.com</p>
</div><p><strong>Media:</strong></p>
<div class="lb-trans"><p><strong>媒体：</strong></p>
</div><p>Sofia Bermudez</p>
<div class="lb-trans"><p>Sofia Bermudez</p>
</div><p>LifeSci Communications</p>
<div class="lb-trans"><p>LifeSci Communications</p>
</div><p>sbermudez@lifescicomms.com</p>
<div class="lb-trans"><p>sbermudez@lifescicomms.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjME9EQTFOaU0zTmpZME9URTJJekl5TmpFM01UUT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTc0ODA1NiM3NjY0OTE2IzIyNjE3MTQ="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGYzOWFjYmYtMDg3Yi00YjM0LWE0OTctOWZiM2E4MjI4MDE5LTEyNzMyNjQtMjAyNi0wNi0xOS1lbg==/tiny/CAMP4-Therapeutics.png" alt="" original-src="https://ml.globenewswire.com/media/NGYzOWFjYmYtMDg3Yi00YjM0LWE0OTctOWZiM2E4MjI4MDE5LTEyNzMyNjQtMjAyNi0wNi0xOS1lbg==/tiny/CAMP4-Therapeutics.png"/></p>

CAMP4 Therapeutics 宣布根据纳斯达克上市规则 5635(c)(4) 授予诱导性股票 | CAMP 股票新闻